论文部分内容阅读
目的:探讨恩度联合同步放化疗治疗中晚期食管癌的临床疗效。方法:选取中晚期食管癌患者78例,随机分为治疗组40例和对照组38例。对照组采用同步放化疗治疗,治疗组在对照组基础上加用恩度。判断两组的疗效和1、2年生存率。结果:随访2年后,治疗组的总有效率为83.8%,总受益率为100.0%;对照组总有效率55.5%,总受益率为91.6%,两组差异有统计学意义(P<0.05);治疗组1年生存率为81.1%,2年生存率为56.8%,对照组分别为58.3%和36.1%,两组相比,差异有统计学差异(P<0.05)。结论:恩度联合同步放化疗可以提高中晚期食管癌的疗效,延长1、2年生存率,但是远期疗效仍待进一步观察。
Objective: To investigate the clinical efficacy of Endue combined with concurrent chemoradiotherapy in the treatment of advanced esophageal cancer. Methods: 78 patients with advanced esophageal cancer were selected and randomly divided into treatment group (40 cases) and control group (38 cases). The control group treated with concurrent radiotherapy and chemotherapy, the treatment group in the control group based on the use of grace. To determine the two groups of efficacy and 1, 2-year survival rate. Results: After 2 years of follow-up, the total effective rate was 83.8% in the treatment group and the total benefit rate was 100.0%. The total effective rate in the control group was 55.5% and the total benefit rate was 91.6%. The difference was statistically significant (P <0.05 ). The 1-year survival rate was 81.1% and the 2-year survival rate was 56.8% in the treatment group and 58.3% and 36.1% in the control group, respectively. There was significant difference between the two groups (P <0.05). Conclusions: Endo combined with concurrent chemoradiotherapy can improve the efficacy of advanced esophageal cancer and prolong the one-year and two-year survival rate, but the long-term efficacy remains to be further observed.